Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
NCT ID: NCT04554160
Last Updated: 2024-04-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
40 participants
Study Classification
OBSERVATIONAL
Study Start Date
2018-09-24
Study Completion Date
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Arrhythmias are considered a prominent phenomenon in pulmonary hypertension (PH) as the disease progresses. According primarily to retrospective studies with up to 24 hours of monitoring, supraventricular tachycardias (SVT) can be found in 8-35% of patients, with significant impact on survival.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24 hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial hypertension (PAH).
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
Currently the the loop-recorder is considered the gold standard for long-term continuous cardiac montoring. A non-invasive continuous monitoring could be of a great benefit for the patients, and could potentially contribute to treatment optimization.
The study will assess apple watches as a non-invasive tool compared to to the loop recorder, which is considered as the current gold standard.
Additionally, the study seeks to assess apple watches for monitoring as an independent wearable for risk assessment in PH.
Furthermore, a few prospective studies to date deploying short-term monitoring (10 minutes-24 hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial hypertension (PAH).
In ASPIRE arrhythmias and heart rate variability is being assessed via long term monitoring.
Currently the the loop-recorder is considered the gold standard for long-term continuous cardiac montoring. A non-invasive continuous monitoring could be of a great benefit for the patients, and could potentially contribute to treatment optimization.
The study will assess apple watches as a non-invasive tool compared to to the loop recorder, which is considered as the current gold standard.
Additionally, the study seeks to assess apple watches for monitoring as an independent wearable for risk assessment in PH.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary Hypertension and Arrhythmia
NCT05496504
Pulmonary Hypertension
COMPLETED
Diagnostic Accuracy in the Detection of Arrhythmias of Patient Recorded ECGs With Smart WATCH TIMEly Performed During Palpitations
NCT06482320
Arrhythmia
RECRUITING
Screening of Cardiac Arrhythmias With Wrist-worn Aino ECG Cardiac Monitor
NCT05196412
Arrhythmias, Cardiac
Atrial Fibrillation
COMPLETED
NA
Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy
NCT03259113
Hypertrophic Cardiomyopathy
UNKNOWN
NA
7-day Holter Monitoring in Adult Patients With Recent IS or TIA, to Measure the Prevalence of Paroxysmal Atrial Fibrillation Including Episodes Less Than 30 Seconds: Transversal Study
NCT04963647
Atrial Fibrillation
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In general there is a lack of evidence of the arrhythmic burden in PH. The present study is the first to apply continuous long-term cardiac monitoring in patients with PH to describe the prevalence of arrhythmias in PH by continuous long-term cardiac monitoring. Furthermore, the correlation between heart rate variability and risk assessment parameters including WHO functional class (FC), NT-proBNP, 6MWT, cardiac parameters and cardiac function will be studies.
A few prospective studies have demonstrated lower HRV in PH than in healthy individuals, however only based on short-term monitoring (20 minutes to 24 hour) and only in a few patients. In retrospective studies, a higher mortality in children with PAH and low HRV has been shown with 24 hour Holter monitoring. Consequently, there is a lack of evidence regarding right heart failure and the prognostic value of HRV.
Risk assessment in PH is essential in the selection of treatment in PH and for prognosis in the study ASPIRE the investigators will assess the use of heart rate variability in pulmonary hypertension.
In conclusion the ASPIRE study will:
1. Assess the incidence and prevalence of arrhythmias using long term cardiac monitoring via a reveal LINQ loop recorder (Medtronic). Furthermore, the investigators will assess; Change in cardiac index, right atrial size, RV size, fibrosis and stroke volume.
2. The investigators will assess the arrhythmic burden in relation to:
* Change in 6 MWT
* Hemodynamic changes with RHC
* Hemodynamic changes in echocardiography
* The number of patients progressing one FC (Modified NYHA class)
* Changes in NT-proBNP.
* Hospital admission for any reason
* Death or transplantation
3. Monitor heart rate variability and address a comparison to known risk markers and CMR and echocardiography.
The study specifically seeks to investigate following:
* The incidence and type of supraventricular and ventricular arrhythmias in PH by continuous long-term monitoring
* The predictive value of both right and left ventricular cardiac magnetic resonance (CMR) imaging parameters for arrhythmogenesis in PAH, heart rate variability, and heart rate.
* Optimization of specific therapy in PAH using continuous long-term arrhythmia monitoring
4. Monitor patients using smart watches (apple watches) to evaluate the applicability of long-term monitoring via apple watches in patients with pulmonary hypertension for irsk asessment.
A few prospective studies have demonstrated lower HRV in PH than in healthy individuals, however only based on short-term monitoring (20 minutes to 24 hour) and only in a few patients. In retrospective studies, a higher mortality in children with PAH and low HRV has been shown with 24 hour Holter monitoring. Consequently, there is a lack of evidence regarding right heart failure and the prognostic value of HRV.
Risk assessment in PH is essential in the selection of treatment in PH and for prognosis in the study ASPIRE the investigators will assess the use of heart rate variability in pulmonary hypertension.
In conclusion the ASPIRE study will:
1. Assess the incidence and prevalence of arrhythmias using long term cardiac monitoring via a reveal LINQ loop recorder (Medtronic). Furthermore, the investigators will assess; Change in cardiac index, right atrial size, RV size, fibrosis and stroke volume.
2. The investigators will assess the arrhythmic burden in relation to:
* Change in 6 MWT
* Hemodynamic changes with RHC
* Hemodynamic changes in echocardiography
* The number of patients progressing one FC (Modified NYHA class)
* Changes in NT-proBNP.
* Hospital admission for any reason
* Death or transplantation
3. Monitor heart rate variability and address a comparison to known risk markers and CMR and echocardiography.
The study specifically seeks to investigate following:
* The incidence and type of supraventricular and ventricular arrhythmias in PH by continuous long-term monitoring
* The predictive value of both right and left ventricular cardiac magnetic resonance (CMR) imaging parameters for arrhythmogenesis in PAH, heart rate variability, and heart rate.
* Optimization of specific therapy in PAH using continuous long-term arrhythmia monitoring
4. Monitor patients using smart watches (apple watches) to evaluate the applicability of long-term monitoring via apple watches in patients with pulmonary hypertension for irsk asessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pulmonary Hypertension
Arrhythmias, Cardiac
Heart Rate Variability
Risk Assessment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Loop recorder implantation
A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
Intervention Type
DEVICE
A smartwatch
A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
Intervention Type
DEVICE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Reveal LINQ loop recorder
Apple watch
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pulmonary hypertension patients \>18 years of age
* Voluntary participation after giving informed verbal and written consent
* Patients naïve to PAH-specific treatments
* Patients on current PAH specific medication independent of duration of therapy
* Patients can be in WHO group 1 classified by one of the following subgroups:
* Idiopathic pulmonary arterial hypertension (IPAH)
* Heritable pulmonary arterial hypertension (HPAH)
* Drugs and toxins
* Associated with (APAH): specifically, connective tissue disease (CTD), HIV infection and congenital heart disease
* Patients with chronic thromboembolic pulmonary hypertension
* Diagnosis of PAH confirmed by right heart catheterization
* WHO/NYHA functional class II to IV symptoms
* 6MWT distances of ≥50 meters and within 15% of each other on 2 consecutive tests preferably performed on different days during Screening.
* Voluntary participation after giving informed verbal and written consent
* Patients naïve to PAH-specific treatments
* Patients on current PAH specific medication independent of duration of therapy
* Patients can be in WHO group 1 classified by one of the following subgroups:
* Idiopathic pulmonary arterial hypertension (IPAH)
* Heritable pulmonary arterial hypertension (HPAH)
* Drugs and toxins
* Associated with (APAH): specifically, connective tissue disease (CTD), HIV infection and congenital heart disease
* Patients with chronic thromboembolic pulmonary hypertension
* Diagnosis of PAH confirmed by right heart catheterization
* WHO/NYHA functional class II to IV symptoms
* 6MWT distances of ≥50 meters and within 15% of each other on 2 consecutive tests preferably performed on different days during Screening.
Exclusion Criteria
* Presence of 3 or more of the following risk factors for heart failure with preserved ejection fraction at Screening: BMI \>30 kg/m2; diabetes mellitus of any type; systemic hypertension, significant coronary artery disease; or left atrial volume index (LAVi) \>30 mL/m2.
* Evidence or history of left-sided heart disease and/or clinically significant cardiac disease.
* Acutely decompensated heart failure within 30 days prior to Screening
* Evidence of significant parenchymal lung disease
* Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (SBP) \>160 mmHg or sitting diastolic blood pressure (DBP) \>100 mmHg at Screening. • Systolic blood pressure \>160 mmHg or \< 90 mmHg; or diastolic blood pressure \> 100 mgHg at Screening
* Male subjects with a corrected QT interval using Fridericia's formula (QTcF) \>450 msec, and female subjects with QTcF \>470 msec on ECG measured at Screening or Baseline.
* Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or that would confound study analysis or impair study participation or cooperation
* Evidence or history of left-sided heart disease and/or clinically significant cardiac disease.
* Acutely decompensated heart failure within 30 days prior to Screening
* Evidence of significant parenchymal lung disease
* Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (SBP) \>160 mmHg or sitting diastolic blood pressure (DBP) \>100 mmHg at Screening. • Systolic blood pressure \>160 mmHg or \< 90 mmHg; or diastolic blood pressure \> 100 mgHg at Screening
* Male subjects with a corrected QT interval using Fridericia's formula (QTcF) \>450 msec, and female subjects with QTcF \>470 msec on ECG measured at Screening or Baseline.
* Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or that would confound study analysis or impair study participation or cooperation
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Sponsor Role
collaborator
Rigshospitalet, Denmark
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jørn Carlsen
Principal investigator, MD, DMSc
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jørn Carlsen, MD, DMSC
Role: STUDY_DIRECTOR
MD at Copenhagen University Hospital, Rigshospitalet 9- Blegdamsvej
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology 2141 Copenhagen University Hospital, Rigshospitalet 9- Blegdamsvej
Copenhagen, , Denmark
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
Reference Type
BACKGROUND
Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007 Jan;153(1):127-32. doi: 10.1016/j.ahj.2006.09.008.
Reference Type
BACKGROUND
Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, Liu QQ, Wang L, Zhao QH, He J, Jing ZC. Frequency of supraventricular arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol. 2014 Nov 1;114(9):1420-5. doi: 10.1016/j.amjcard.2014.07.079. Epub 2014 Aug 13.
Reference Type
BACKGROUND
Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol. 2013 Sep 1;167(5):2300-5. doi: 10.1016/j.ijcard.2012.06.024. Epub 2012 Jun 22.
Reference Type
BACKGROUND
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. No abstract available.
Reference Type
BACKGROUND
Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management. Arrhythm Electrophysiol Rev. 2018 Mar;7(1):43-48. doi: 10.15420/aer.2018.3.2.
Reference Type
BACKGROUND
Mercurio V, Peloquin G, Bourji KI, Diab N, Sato T, Enobun B, Housten-Harris T, Damico R, Kolb TM, Mathai SC, Tedford RJ, Tocchetti CG, Hassoun PM. Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. Pulm Circ. 2018 Apr-Jun;8(2):2045894018769874. doi: 10.1177/2045894018769874. Epub 2018 Mar 26.
Reference Type
BACKGROUND
Cannillo M, Grosso Marra W, Gili S, D'Ascenzo F, Morello M, Mercante L, Mistretta E, Salera D, Zema D, Bissolino A, Fusaro E, Marra S, Libertucci D, Gaita F. Supraventricular Arrhythmias in Patients With Pulmonary Arterial Hypertension. Am J Cardiol. 2015 Dec 15;116(12):1883-9. doi: 10.1016/j.amjcard.2015.09.039. Epub 2015 Oct 9.
Reference Type
BACKGROUND
Cirulis MM, Ryan JJ, Archer SL. Pathophysiology, incidence, management, and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Pulm Circ. 2019 Jan-Mar;9(1):2045894019834890. doi: 10.1177/2045894019834890.
Reference Type
BACKGROUND
Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012 Sep-Oct;55(2):180-6. doi: 10.1016/j.pcad.2012.06.002.
Reference Type
BACKGROUND
Folino AF, Bobbo F, Schiraldi C, Tona F, Romano S, Buja G, Bellotto F. Ventricular arrhythmias and autonomic profile in patients with primary pulmonary hypertension. Lung. 2003 Nov-Dec;181(6):321-8. doi: 10.1007/s00408-003-1034-x.
Reference Type
BACKGROUND
da Silva Goncalves Bos D, Van Der Bruggen CEE, Kurakula K, Sun XQ, Casali KR, Casali AG, Rol N, Szulcek R, Dos Remedios C, Guignabert C, Tu L, Dorfmuller P, Humbert M, Wijnker PJM, Kuster DWD, van der Velden J, Goumans MJ, Bogaard HJ, Vonk-Noordegraaf A, de Man FS, Handoko ML. Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation. 2018 Feb 27;137(9):910-924. doi: 10.1161/CIRCULATIONAHA.117.027451. Epub 2017 Nov 22.
Reference Type
BACKGROUND
Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008 May 6;51(18):1725-33. doi: 10.1016/j.jacc.2008.01.038.
Reference Type
BACKGROUND
Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2011 Dec;20(122):243-53. doi: 10.1183/09059180.00006511.
Reference Type
BACKGROUND
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33. doi: 10.1016/j.jacc.2013.10.027.
Reference Type
BACKGROUND
Smith B, Genuardi MV, Koczo A, Zou RH, Thoma FW, Handen A, Craig E, Hogan CM, Girard T, Althouse AD, Chan SY. Atrial arrhythmias are associated with increased mortality in pulmonary arterial hypertension. Pulm Circ. 2018 Jul-Sep;8(3):2045894018790316. doi: 10.1177/2045894018790316. Epub 2018 Jul 3.
Reference Type
BACKGROUND
Li YH, Tholakanahalli Z, Adabag JM, Wang Z, Li J. [Effectiveness and accuracy of arrhythmia detection algorithm with the Reveal LINQ insertable cardiac monitor]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Jun 24;46(6):470-474. doi: 10.3760/cma.j.issn.0253-3758.2018.06.011. Chinese.
Reference Type
BACKGROUND
Wensel R, Jilek C, Dorr M, Francis DP, Stadler H, Lange T, Blumberg F, Opitz C, Pfeifer M, Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J. 2009 Oct;34(4):895-901. doi: 10.1183/09031936.00145708. Epub 2009 May 14.
Reference Type
BACKGROUND
Shaffer F, McCraty R, Zerr CL. A healthy heart is not a metronome: an integrative review of the heart's anatomy and heart rate variability. Front Psychol. 2014 Sep 30;5:1040. doi: 10.3389/fpsyg.2014.01040. eCollection 2014.
Reference Type
BACKGROUND
Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017.
Reference Type
BACKGROUND
Smilde TD, van Veldhuisen DJ, van den Berg MP. Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol. 2009 Apr;98(4):233-9. doi: 10.1007/s00392-009-0747-0. Epub 2009 Feb 13.
Reference Type
BACKGROUND
Huikuri HV, Stein PK. Heart rate variability in risk stratification of cardiac patients. Prog Cardiovasc Dis. 2013 Sep-Oct;56(2):153-9. doi: 10.1016/j.pcad.2013.07.003. Epub 2013 Aug 12.
Reference Type
BACKGROUND
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.
Reference Type
BACKGROUND
Galinier M, Pathak A, Fourcade J, Androdias C, Curnier D, Varnous S, Boveda S, Massabuau P, Fauvel M, Senard JM, Bounhoure JP. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J. 2000 Mar;21(6):475-82. doi: 10.1053/euhj.1999.1875.
Reference Type
BACKGROUND
Lammers AE, Munnery E, Hislop AA, Haworth SG. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol. 2010 Jul 9;142(2):159-65. doi: 10.1016/j.ijcard.2008.12.087. Epub 2009 Jan 26.
Reference Type
BACKGROUND
Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998 Mar 1;31(3):593-601. doi: 10.1016/s0735-1097(97)00554-8.
Reference Type
BACKGROUND
Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014 May 23;114(11):1815-26. doi: 10.1161/CIRCRESAHA.114.302589.
Reference Type
BACKGROUND
Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD, Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res. 2006 Jun 1;70(3):434-45. doi: 10.1016/j.cardiores.2006.01.013. Epub 2006 Feb 14.
Reference Type
BACKGROUND
Yi HT, Hsieh YC, Wu TJ, Huang JL, Lin WW, Liang KW, Su CS, Tsai WJ, Wang KY. Heart rate variability parameters and ventricular arrhythmia correlate with pulmonary arterial pressure in adult patients with idiopathic pulmonary arterial hypertension. Heart Lung. 2014 Nov-Dec;43(6):534-40. doi: 10.1016/j.hrtlng.2014.05.010. Epub 2014 Jun 11.
Reference Type
BACKGROUND
Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Paul Fauchier J. Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail. 2004 Mar 1;6(2):181-5. doi: 10.1016/j.ejheart.2003.09.007.
Reference Type
BACKGROUND
Tsai CH, Ma HP, Lin YT, Hung CS, Hsieh MC, Chang TY, Kuo PH, Lin C, Lo MT, Hsu HH, Peng CK, Lin YH. Heart Rhythm Complexity Impairment in Patients with Pulmonary Hypertension. Sci Rep. 2019 Jul 24;9(1):10710. doi: 10.1038/s41598-019-47144-1.
Reference Type
BACKGROUND
Weatherald J, Boucly A, Sitbon O. Risk stratification in pulmonary arterial hypertension. Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510.
Reference Type
BACKGROUND
Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin VV, Preiss R, Simonneau G, Sitbon O, Tapson VF. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation. 2019 May 21;139(21):2440-2450. doi: 10.1161/CIRCULATIONAHA.118.039360.
Reference Type
BACKGROUND
Sanders P, Purerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, Dekker LR; Reveal LINQ Usability Investigators. Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm. 2016 Jul;13(7):1425-30. doi: 10.1016/j.hrthm.2016.03.005. Epub 2016 Mar 4.
Reference Type
BACKGROUND
Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014 Apr 25;114(9):1453-68. doi: 10.1161/CIRCRESAHA.114.303211.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-18005164
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Atrial Function and Supraventricular Arrhythmia of the Veteran Athlete.
NCT03665324
COMPLETED
Dipole Density Mapping in Supraventricular Tachycardia
NCT02469623
COMPLETED
NA
Telemetric Arrhythmia Diagnosis in Adults
NCT01265758
UNKNOWN
NA
Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy
NCT01265303
UNKNOWN
NA
Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients
NCT01271816
TERMINATED
Long-term Pacemaker Arrhythmia Analysis
NCT02016950
COMPLETED
Dipole Density Mapping of Right and Left Atrial Supraventricular Tachycardia
NCT01914575
WITHDRAWN
NA
Diagnosis of Arrhythmias in Syncope by Pocket-ECG III® or Conventional Holter
NCT02614235
COMPLETED
NA
Obstructive Sleep Apnoea and Cardiac Arrhythmias
NCT03866148
ACTIVE_NOT_RECRUITING
NA
The Rhytmia System to Determine the Precise Location and Potential Mechanism of Premature Contractions
NCT03460535
UNKNOWN
Non-invasive Differentiation of Supraventricular Tachyarrhythmia
NCT06061120
RECRUITING
Full Disclosure Observational Cardiac Rhythm Documentation Follow-up After Surgical Atrial Fibrillation Therapy
NCT00806689
UNKNOWN
Smart Watch iECG for the Detection of Cardiac Arrhythmias
NCT04092985
COMPLETED
Left Bundle Branch Pacing Versus Right Ventricular Pacing in Patients With Atrioventricular Block
NCT05722379
UNKNOWN
Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment
NCT05575557
UNKNOWN
NA
A Comparative Study of an Innovative 3-lead Wireless Water Resistant Holter System and a Conventional Holter System
NCT04723355
COMPLETED
NA
A Prospective Incident Study of Arrhythmias in Hypertrophic Cardiomyopathy
NCT04112290
ACTIVE_NOT_RECRUITING
Systematic Assessment of Treatment Effectiveness for Long-Term Management of Stable Atrial Tachycardia in Inpatient and Outpatient Environments
NCT07239804
ACTIVE_NOT_RECRUITING
Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB
NCT03614169
COMPLETED
NA
Cardiac Arrhythmias at Extreme Altitude
NCT05676398
UNKNOWN
Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension
NCT01905189
UNKNOWN
NA
Hypertrophic Cardiomyopathy Pilot Study
NCT02806479
COMPLETED
Ultra-high-frequency ECG for Prediction of Left Ventricular Remodeling
NCT04908033
ACTIVE_NOT_RECRUITING
Characterization of Arrhythmia-induced Cardiomyopathy
NCT05662293
RECRUITING
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
NCT06730464
RECRUITING